Thomas L. Andresen

Thomas L. Andresen has extensive work experience in the biotechnology and pharmaceutical industries. Thomas L. is currently serving as the Chief Executive Officer at T-Cypher Bio, a position they have held since August 2021. Prior to that, they co-founded X-Therapeutics in 2018 and continues to be involved with the company. Thomas L. is also a co-founder and board member of MonTa Biosciences since December 2016.

Thomas has a strong academic background and has held various roles at the DTU - Technical University of Denmark. Thomas L. served as an Adjunct Professor starting from August 2016 and later became the Director and Chair of the Institute of Health Technology from September 2019 to August 2021. Thomas L. has also held positions as the Director and Chair of the Institute for Micro- and Nanotechnology, Head of the Center for Nanomedicine and Theranostics, Co-Director of the Institute of Micro- and Nanotechnology, and Professor at the university.

In addition to their academic work, Thomas co-founded Nanovi A/S in 2012 and has been involved as a board member and chair of the board. Thomas L. also served as the Chief Scientific Officer at Nanovi A/S from January 2012 to January 2016. Furthermore, they have contributed to Repertoire Immune Medicines as the Chief Scientific Officer from January 2018 to March 2020, and as a co-founder from August 2015 to December 2019.

Thomas has also worked as a Scientific Advisor at Lipoid - Phospholipid Research Center from September 2017 to August 2019. Prior to that, they held the position of Senior Scientist & Group Leader at Risø National Laboratory from December 2006 to December 2007, and as the Head Of Research and Development at LiPlasome Pharma A/S from January 2001 to December 2006.

Thomas L. Andresen completed their education at DTU - Technical University of Denmark. From 1996 to 2001, they pursued a Master of Science (MSc) degree in Chemistry. Following this, Thomas L. Andresen went on to obtain a Doctor of Philosophy (PhD) degree in Drug Delivery, which they completed between 2001 and 2005.